ERBB2 and breast carcinoma: Based on this result, a randomized phase 2 trial of lapatinib combined with pazopanib versus lapatinib alone was conducted in patients with relapsed HER2+ IBC (ClinicalTrials.gov Identifier: NCT00558103; A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-expressing Inflammatory Breast Cancer; Table 1).